FindTrial
Sign In

Comparison between Radioembolization and Transarterial chemoembolization in liver cancer treatment

Comparison between Radioembolization with 131I-Lipiodol and Transarterial chemoembolization in Hepatocellular carcinoma treatment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8w9rzy
Enrollment
Unknown
Registered
2020-01-07
Start date
2019-09-05
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Transarterial radioembolization and transarterial chemoembolization. Intervention group: 20 pacients submitted to radioembolization, when 3,5 ml of radioactive iodine (I131) (equivalent to 60 mCI) wil
Procedure/surgery
Radiation
E02.520.360.150

Sponsors

Faculdade de Medicina de Botucatu/ Universidade Estadual Paulista
Lead Sponsor
Faculdade de Medicina de Botucatu/ Universidade Estadual Paulista
Collaborator

Eligibility

Age
18 Years to 130 Years

Inclusion criteria

Inclusion criteria: Age of 18 years-old or older; hepatocellular carcinoma graded as intermediate or advanced; liver cirrhosis; performance status of 0 or 1 at the time of the treatment; with contrast-administrated imaging exams before the treatment to assess the treatment response.

Exclusion criteria

Exclusion criteria: Another neoplastic disease; incomplete study procedures; lack of imaging exams during the follow-up; other severe ilnesses in advanced stage that could be more harmful to the patient survival than the hepatocellular carcinoma and the liver cirrhosis, such as chronic obstructive pulmonar disease, cardiac insuficiency, immunosupression (caused by HIV infection or drug-induced) or dialytic kidney insuficiency; pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
To assess the locoregional response according to the modified RECIST criteria, calculated by the measures of the tumor size in the arterial phase of the computadorized tomography performed before and after the procedures, in squared milimeters. ;To evaluate the changes of the tumor area in the arterial phase observed in the iodine-contrasted computed tomography, in squared milimeters.—

Secondary

MeasureTime frame
To assess the time to progression and the overall survival, measured in days.;To measure the time frame in which the patient lives without any signs of tumor progression and the time frame between the procedure and the patient death, measured in days.—

Countries

Brazil

Contacts

Public ContactFernando Romeiro

Faculdade de Medicina de Botucatu/ Universidade Estadual Paulista

fgromeiro@gmail.com+55-014-38801171

Outcome results

None listed

Source: REBEC (via WHO ICTRP)